Edgewise Therapeutics Reveals Promising Sevasemten Data for Becker Muscular Dystrophy with Long-Term Stabilization Results Edgewise Therapeutics announces positive long-term results of Sevasemten, showing functional stabilization in Becker muscular dystrophy over 3.5 years, with expectations to progress to marketing application.

Edgewise Therapeutics Reveals Promising Sevasemten Data for Becker Muscular Dystrophy with Long-Term Stabilization Results #United_States #Boulder #Edgewise_Therapeutics #Sevasemten #Becker_muscular_dystrophy

Edgewise Therapeutics to Share Sevasemten Advances at MDA 2026 Conference Edgewise Therapeutics announces its participation in the 2026 MDA Clinical Conference, focusing on new data about Sevasemten for Becker Muscular Dystrophy treatments.

Edgewise Therapeutics to Share Sevasemten Advances at MDA 2026 Conference #USA #Orlando #Edgewise_Therapeutics #Sevasemten #Becker_muscular_dystrophy

Edgewise Therapeutics Unveils Financial Progress and Upcoming Milestones for 2025 and Beyond Edgewise Therapeutics has revealed its financial results for 2025, showcasing strong advancements in muscular dystrophy and cardiovascular programs.

Edgewise Therapeutics Unveils Financial Progress and Upcoming Milestones for 2025 and Beyond #USA #Boulder #Edgewise_Therapeutics #Sevasemten #EWTX

Edgewise Therapeutics Unveils Q3 2025 Financial Results and Future Prospects Edgewise Therapeutics shares its financial results for Q3 2025, highlighting key developments in muscular and cardiac treatments and future plans.

Edgewise Therapeutics Unveils Q3 2025 Financial Results and Future Prospects #United_States #Boulder #Edgewise_Therapeutics #EDG-7500 #Sevasemten

Edgewise Therapeutics to Showcase Sevasemten's Efficacy for Muscular Dystrophies at the WMS 2025 Congress Edgewise Therapeutics will present vital data on Sevasemten for Becker and Duchenne muscular dystrophies at the World Muscle Society Congress, highlighting its promising impacts.

Edgewise Therapeutics to Showcase Sevasemten's Efficacy for Muscular Dystrophies at the WMS 2025 Congress #None #Vienna #Muscular_Dystrophy #Edgewise_Therapeutics #Sevasemten

Edgewise Therapeutics Posts Robust Q2 2025 Results with Significant Clinical Advances Edgewise Therapeutics shares its strong Q2 2025 financial performance, highlighting vital advancements in therapies for muscle diseases and ongoing trials.

Edgewise Therapeutics Posts Robust Q2 2025 Results with Significant Clinical Advances #United_States #Boulder #Edgewise_Therapeutics #Sevasemten #Becker_muscular_dystrophy

Edgewise Therapeutics Unveils Promising Financials and Key Developments for Q1 2025 Edgewise Therapeutics announced its financial performance and major achievements for the first quarter of 2025, showcasing promising results in various clinical trials.

Edgewise Therapeutics Unveils Promising Financials and Key Developments for Q1 2025 #United_States #Boulder #Edgewise_Therapeutics #EDG-7500 #Sevasemten

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy🎉💯

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #edgewise #sevasemten